Mason Carrico
Stock Analyst at Stephens & Co.
(2.32)
# 1,456
Out of 4,667 analysts
55
Total ratings
42.55%
Success rate
-0.14%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Maintains: Overweight | $170 → $184 | $131.68 | +39.73% | 6 | Nov 12, 2024 | |
| TXG 10x Genomics | Reiterates: Overweight | $30 | $13.32 | +125.23% | 5 | Oct 10, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $3.5 → $2.5 | $1.72 | +45.35% | 2 | Aug 13, 2024 | |
| NTRA Natera | Reiterates: Overweight | $125 | $167.88 | -25.54% | 4 | Aug 9, 2024 | |
| CSTL Castle Biosciences | Reiterates: Overweight | $37 | $28.45 | +30.05% | 6 | Aug 6, 2024 | |
| HOLX Hologic | Reiterates: Overweight | $92 | $78.04 | +17.89% | 2 | Jul 30, 2024 | |
| NEO NeoGenomics | Reiterates: Overweight | $19 | $15.36 | +23.70% | 1 | Jul 30, 2024 | |
| GH Guardant Health | Reiterates: Overweight | $44 | $30.68 | +43.42% | 4 | May 24, 2024 | |
| CDNA CareDx | Maintains: Overweight | $15 → $18 | $22.37 | -19.54% | 8 | May 13, 2024 | |
| OCX OncoCyte | Reiterates: Equal-Weight | $4 | $2.75 | +45.45% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.13 | +46.82% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $9 | $2.16 | +316.67% | 4 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $39.20 | -13.27% | 6 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $24 | $15.30 | +56.86% | 3 | May 4, 2023 |
Illumina
Nov 12, 2024
Maintains: Overweight
Price Target: $170 → $184
Current: $131.68
Upside: +39.73%
10x Genomics
Oct 10, 2024
Reiterates: Overweight
Price Target: $30
Current: $13.32
Upside: +125.23%
Pacific Biosciences of California
Aug 13, 2024
Maintains: Overweight
Price Target: $3.5 → $2.5
Current: $1.72
Upside: +45.35%
Natera
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $167.88
Upside: -25.54%
Castle Biosciences
Aug 6, 2024
Reiterates: Overweight
Price Target: $37
Current: $28.45
Upside: +30.05%
Hologic
Jul 30, 2024
Reiterates: Overweight
Price Target: $92
Current: $78.04
Upside: +17.89%
NeoGenomics
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $15.36
Upside: +23.70%
Guardant Health
May 24, 2024
Reiterates: Overweight
Price Target: $44
Current: $30.68
Upside: +43.42%
CareDx
May 13, 2024
Maintains: Overweight
Price Target: $15 → $18
Current: $22.37
Upside: -19.54%
OncoCyte
Apr 17, 2024
Reiterates: Equal-Weight
Price Target: $4
Current: $2.75
Upside: +45.45%
Dec 14, 2023
Initiates: Overweight
Price Target: $9
Current: $6.13
Upside: +46.82%
Nov 13, 2023
Maintains: Overweight
Price Target: $14 → $9
Current: $2.16
Upside: +316.67%
Oct 10, 2023
Reiterates: Overweight
Price Target: $34
Current: $39.20
Upside: -13.27%
May 4, 2023
Reiterates: Equal-Weight
Price Target: $24
Current: $15.30
Upside: +56.86%